UK markets closed

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
17.85-0.37 (-2.03%)
As of 12:58PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 4.08B
Enterprise value 2.56B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)52.40
Price/book (mrq)5.18
Enterprise value/revenue 37.82
Enterprise value/EBITDA -5.93

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-81.55%
S&P500 52-week change 314.56%
52-week high 3133.00
52-week low 316.56
50-day moving average 335.78
200-day moving average 362.95

Share statistics

Avg vol (3-month) 3733.58k
Avg vol (10-day) 31.02M
Shares outstanding 5186.95M
Implied shares outstanding 6N/A
Float 884.3M
% held by insiders 155.06%
% held by institutions 123.48%
Shares short (30 Dec 2021) 44.16M
Short ratio (30 Dec 2021) 45.94
Short % of float (30 Dec 2021) 45.45%
Short % of shares outstanding (30 Dec 2021) 42.22%
Shares short (prior month 29 Nov 2021) 43.73M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in EUR.

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)-781.82%

Management effectiveness

Return on assets (ttm)-24.68%
Return on equity (ttm)-64.25%

Income statement

Revenue (ttm)67.81M
Revenue per share (ttm)0.37
Quarterly revenue growth (yoy)-53.10%
Gross profit (ttm)34.75M
EBITDA -520.2M
Net income avi to common (ttm)-467.93M
Diluted EPS (ttm)-2.88
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.4B
Total cash per share (mrq)7.46
Total debt (mrq)55.69M
Total debt/equity (mrq)6.67
Current ratio (mrq)1.79
Book value per share (mrq)3.72

Cash flow statement

Operating cash flow (ttm)-108.64M
Levered free cash flow (ttm)-97.93M